Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix

Editor Note: For more information about this release, please scroll to bottom.

LONDON, January 8, 2014 /PRNewswire/ --

On Tuesday, January 07, 2014, the US equity market ended on a higher note as the S&P 500 ended the day at 1,837.88, up 0.61%; the Dow Jones Industrial Average closed at 16,530.94, up 0.64%; and the NASDAQ Composite finished at 4,153.18, up 0.96%. The S&P 500 Health Care Sector Index advanced 1.01% to end the day at 644.13. The S&P 500 Pharmaceuticals Sub Industry Index ended the day at 491.51, up 0.94%; and the same has advanced 1.30% in the previous three trading sessions and 9.12% in the last three months, compared to a gain of 0.32% and 9.65% in the S&P 500 during the respective periods. The major movers in the industry included Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Zogenix Inc. (NASDAQ: ZGNX). All these companies are tracked by AAAResearchReports.com. Free technical research on PFE, MRK, ABBV, and ZGNX can be downloaded upon signing up at:

http://www.aaaresearchreports.com/register/  

On Tuesday, Pfizer Inc.'s stock posted gains to end the day at $30.74, up 0.62% from the previous day's closing price of $30.55. The company's shares oscillated between $30.74 and $31.02 during the trading session. A total of 22.21 million shares were traded, which is below the daily average volume of 25.10 million. The company's shares have gained 0.92% in the previous three trading sessions and 7.41% in the last three months, compared to a gain of 0.32% and 9.65% in the S&P 500 during the respective periods. Moreover, Pfizer Inc.'s stock is trading above its 200-day moving average of $29.48. Sign up and read the complimentary report on PFE at:

http://www.AAAResearchReports.com/PFE010814.pdf

Shares in Merck & Co. Inc. edged 0.74% higher on Tuesday, tracking gains in the broader market. The company's shares closed the day at $50.11, after vacillating between $49.94 and $50.40 during the trading session. A total of 10.00 million shares were traded, which is below the daily average volume of 12.38 million. The company's shares have advanced 1.46% in the last one month and 4.64% in the previous three months, underperforming the S&P 500, which has gained 1.82% and 9.65% during the respective periods. Further, Merck & Co. Inc.'s stock is trading near its 52-week high of $50.42, and also above its 50-day and 200-day moving averages of $48.19 and $47.47, respectively. The free report on MRK can be downloaded by signing up now at:

http://www.AAAResearchReports.com/MRK010814.pdf  

On Tuesday's, AbbVie Inc.'s stock finished the day at $50.49, which is 0.20% higher than the previous day's closing price of $50.39. The company's shares fluctuated between $50.30 and $51.21 during the trading session. A total of 9.72 million shares were traded, which is above the daily average volume of 5.58 million. The company's shares have advanced 9.55% in the previous three months, underperforming the S&P 500, which has gained 9.65% during the same period. Additionally, AbbVie Inc.'s stock is trading above its 50-day and 200-day moving averages of $50.14 and $45.68, respectively. A free report on ABBV can be accessed by registering at:

http://www.AAAResearchReports.com/ABBV010814.pdf

Zogenix Inc.'s stock gained 0.60% on Tuesday, ending the day at $3.33. The company's shares oscillated between $3.26 and $3.36 during the trading session. A total of 1.37 million shares were traded, which is below the daily average volume of 2.20 million. The company's shares have gained 2.46% in the last one month and 35.92% in the previous three months, outperforming the S&P 500, which has advanced 1.82% and 9.65% during the respective periods. Furthermore, Zogenix Inc.'s stock is trading above its 50-day and 200-day moving averages of $3.00 and $2.04, respectively. Register with AAA Research Reports and download research on ZGNX for free at:

http://www.AAAResearchReports.com/ZGNX010814.pdf  

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AAAresearchreports.com

 

SOURCE AAA Research Reports

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.